Skip to search formSkip to main contentSkip to account menu

NSC-102816

Known as: NSC 102816, NSC102816 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Azacitidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1980
1980
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Thirteen patients were treated with a hydroxyurea -- 5-azacytidine combination in an attempt to show an increase in therapeutic… 
1978
1978
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated… 
1975
1975
Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
5-Azacytidine is more active when administered parenterally than orally in the treatment of L1210 leukemic mice. Oral… 
1975
1975
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
The biologic and antitumor activity of 5-azacytidine has been well demonstrated in the past. The drug at present is thought to be… 
1975
1975
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
Abstract The biologic and antitumor activity of 5-azacytidine has been well demonstrated in the past. The drug at present is… 
1974
1974
Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
Highly Cited
1973
Highly Cited
1973
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
1972
1972
Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man.
Patients with advanced cancer were given 5-azacytidine labeled at position 4 with radioactive carbon (14C) by either the… 
1972
1972
Phase I study of 5-azacytidine (NSC-102816) .
Thirty patients with various solid tumors were treated with 5-azacytidine. Total doses ranged from 1.0 to 24.0 mg/kg and were… 
1972
1972
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)